Biologic Drug Survival in Psoriasis: A Systematic Review & Comparative Meta-Analysis.

ABSTRACT: Drug survival studies have been utilized to evaluate the real-world effectiveness of biologics used in psoriasis. However, the increasing volume of drug survival data suffers from large variability due to regional differences in drug availability, patient selection and biologic reimbursement. The objective of this study was to conduct a meta-analysis of biologic drug survival to determine comparative effectiveness of the biologics in a real-world setting. Studies reporting drug survival for biologic therapy in psoriasis were identified by a systematic literature search. Hazard ratio data for drug discontinuation were estimated directly from published Kaplan-Meier estimator curves at year 1, 2, and 5 of treatment and compared pairwise for the following biologics: ustekinumab, adalimumab, et

SUBMITTER: Mourad AI 

PROVIDER: S-EPMC8012481 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature